Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease

NCT02585934 is registered in ClinicalTrials.gov with Axovant Sciences Ltd. as lead sponsor.

NCT NCT02585934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02585934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
Axovant Sciences Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2015
Completion date
September 30, 2017
Enrollment
1,315 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease